Category: psoriasis

According to a new study, there is no increased risk of infections in pediatric psoriasis (PsO) patients treated with ustekinumab compared to etanercept or methotrexate.

According to a new study, psoriasis patients are significantly more likely to experience migraines than those without psoriasis.

A new study has evaluated the worldwide prevalence of mental disorders such as depression, anxiety, and suicide in patients with psoriasis. 

According to a recent study, patients with comorbid psoriatic arthritis (PsA) have a slightly decreased treatment response to biologics for psoriasis (PsO) than those without PsA.

According to a recent study, most psoriasis patients view their comorbid obesity as unrelated to their skin condition.

According to a new study, smoking and obesity-related factors such as body mass index and waist and hip circumference, are linked to an increased risk of psoriasis.

A real-world study of psoriasis (PsO) and psoriatic arthritis (PsA) patients with apremilast reported no new adverse events or safety signals with results comparable to previous clinical trials.

A new real-world study showed IL-23 inhibitors to be highly effective for the treatment of chronic plaque psoriasis in both biologic-naïve and biologic-non-naïve patients. 

According to a new study, patients with psoriasis have a 20% greater risk of organ-based comorbidities when compared with the general population.

Patients with psoriasis value skin clearance and symptom control as the most important treatment outcomes, according to a new study.